Ruxolitinib for the treatment of pediatric acute and chronic steroid-refractory graft-versus-host disease: Efficacy, safety, and outcomes.
Nikita V Levkovsky, Anna A Zvyagintseva, Anna A Osipova et al.
✦ AI-curated · Sources linked
In 30 seconds
This single-center retrospective study assessed ruxolitinib in children under 18 years with steroid-refractory graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Among 77 patients with acute and 45 with chronic disease, overall response rates were 83% and 87%, respectively. Three-year overall survival was 70% for acute and 85% for chronic disease. Outcomes did not differ significantly by age below versus at least 12 years. Hematological toxicity was the main adverse event; in chronic disease, initial dose correlated with hematological toxicity and liver function test elevations.
Key findings
- Overall response rates were 83% for acute and 87% for chronic steroid-refractory graft-versus-host disease.
- Three-year overall survival was 70% in acute disease and 85% in chronic disease.
- Age below 12 years did not affect outcomes; acute response was 78% vs. 76% (P = 0.96), and chronic response was 89% vs. 79% (P = 0.14).
- Hematological toxicity was the main adverse event; in chronic disease, initial dose correlated with hematological toxicity and liver function test elevations.
Why it matters
Steroid-refractory graft-versus-host disease is associated with substantial morbidity and mortality, and treatment data in younger children are limited. These retrospective findings describe responses and survival across pediatric age groups, including children younger than the current FDA-approved age threshold stated in the abstract. The toxicity findings also highlight the importance of dose and safety monitoring in further evaluation.
What to keep in mind
The study was retrospective and single-center; the authors state that prospective studies are needed to optimize dosing and long-term monitoring.